Alle Storys
Folgen
Keine Story von Epigenomics AG mehr verpassen.

Epigenomics AG

EANS-News: Epigenomics and Predictive Biosciences Extend Licensing Deal for Prostate Cancer Test

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
Licensing Agreements/Company Information/Molecular diagnostics
BERLIN, PHILADELPHIA, PA and LEXINGTON, MA, November 16, 2010 (euro 
adhoc) - Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer 
diagnostics company, and Predictive Biosciences, a commercial stage, 
fully-integrated developer of novel molecular diagnostic cancer 
assays and a provider of anatomic pathology laboratory products and 
services, today announced that they have extended their licensing 
agreement for the prostate cancer biomarker GSTP1, originally signed 
in April 2009. Under the terms of the original agreement, Predictive 
Biosciences had obtained rights to develop a prostate cancer test 
incorporating this well known DNA methylation biomarker and an option
to license GSTP1 for commercialization of this test as a laboratory 
service in the United States. Based on strong continued progress in 
developing the test, Predictive Biosciences has now executed this 
option, triggering an undisclosed one-time license fee to 
Epigenomics. Epigenomics will also be entitled to royalties on future
sales generated with Predictive Biosciences' prostate cancer test, 
which is still in development.
"Prostate cancer diagnosis suffers from poor specificity of PSA 
screening," said Geert Nygaard, CEO of Epigenomics. "We are therefore
delighted that Predictive Biosciences will be using our biomarker to 
develop a test to improve the diagnostic follow-up of patients with 
high PSA."
"We have been very impressed with the quality of methylated GSTP1 as 
a biomarker for prostate cancer," said Peter Klemm, Ph.D., President 
and Chief Executive Officer of Predictive Biosciences. "This 
biomarker will provide a valuable contribution to the portfolio of 
tests we are commercializing in the field of urologic oncology."
Prostate cancer is one of the most prevalent forms of cancer and the 
leading cause of cancer death in men in the U.S., with more than 
230,000 cases diagnosed annually and more than 1 million prostate 
biopsies performed each year. The methylation of the GSTP1 gene is 
well established as a biomarker of prostate cancer and a test that 
detects methylated GSTP1 DNA in urine or tissue, in combination with 
conventional histopathology, may enable a more accurate diagnosis.
-Ends-
Contact Epigenomics AG
Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel +49 (0) 30 24345 368 
pr@epigenomics.com
www.epigenomics.com
Contact Predictive Biosciences
Predictive Biosciences:
Andy Hu, M.D.
+1 (781) 402-1780 x202
www.predictivebiosci.com
About Epigenomics
Epigenomics AG is a molecular diagnostics company with a focus on the
development of novel products for cancer. Using DNA methylation 
biomarkers, Epigenomics' tests on the market and in development for 
colorectal, lung, and prostate cancer aim at aiding in an earlier and
more accurate diagnosis of these diseases, thereby potentially 
increasing the patient's chances of survival.
For development and global commercialization of IVD test products, 
Epigenomics pursues a dual business strategy in which direct 
commercialization of proprietary diagnostic test products is combined
with non-exclusive licensing to diagnostic industry players with 
broad customer access. Strategic diagnostics industry partners 
include Abbott Molecular, Sysmex Corporation, Quest Diagnostics 
Incorporated, ARUP Laboratories, Inc., and Warnex Laboratories, Inc. 
for diagnostics test products and services, and QIAGEN N.V. for 
sample preparation solutions and research products.
The company is headquartered in Berlin, Germany, and has a wholly 
owned subsidiary, Epigenomics Inc., in Seattle, WA, USA. For more 
information, please visit Epigenomics' website at www.epigenomics.com
About Predictive Biosciences
Predictive Biosciences is a fully?integrated developer of novel 
molecular diagnostic cancer assays and an urology?focused provider of
anatomic pathology laboratory products and services. Leveraging a 
portfolio of patented biomarkers and clinical approaches, the company
is building a unique portfolio of assays for cancer management, first
targeted at bladder and prostate cancer. Predictive Biosciences' 
commercial division, OncoDiagnostic Laboratory (ODL), is a Clinical 
Laboratory Improvement Act (CLIA)?certified anatomic pathology and 
molecular diagnostics lab with a national sales force serving 
urologists and other subspecialty physicians. For additional 
information, please visit www.predictivebiosci.com
Epigenomics' legal disclaimers. This communication expressly or 
implicitly contains certain forward-looking statements concerning 
Epigenomics AG and its business. Such statements involve certain 
known and unknown risks, uncertainties and other factors which could 
cause the actual results, financial condition, performance or 
achievements of Epigenomics AG to be materially different from any 
future results, performance or achievements expressed or implied by 
such forward-looking statements. Epigenomics AG is providing this 
communication as of this date and does not undertake to update any 
forward-looking statements contained herein as a result of new 
information, future events or otherwise.
The information contained in this communication does not constitute 
nor imply an offer to sell or transfer any product, and no product 
based on this technology is currently available for sale by 
Epigenomics in the United States of America. The analytical and 
clinical performance characteristics of any product based on this 
technology which may be sold at some future time by Epigenomics in 
the USA have not been established.
end of announcement                               euro adhoc

Further inquiry note:

Epigenomics AG
Dr. Achim Plum
Sen. VP Corporate Development
Tel: +49 30 24345 368
achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade

Weitere Storys: Epigenomics AG
Weitere Storys: Epigenomics AG
  • 09.11.2010 – 08:46

    EANS-News: EPIGENOMICS AG Releases 9-Months Financial Report

    Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Company Information/9-month report/Molecular diagnostics Berlin, Germany, November 9, 2010 (euro adhoc) - Epigenomics AG (Frankfurt Prime Standard: ECX) reports today its third quarter and nine months financials for the period ended September 30, 2010. Key Financials | | ...

  • 05.11.2010 – 09:01

    EANS-News: Epigenomics Signs Distribution Deal with DPC for Epi proColon in Middle East

    Third distribution agreement for Epi proColon completes the picture for the Middle East Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Company Information/Molecular diagnostics Subtitle: Third distribution agreement for Epi proColon completes the picture for the Middle East BERLIN ...

  • 28.10.2010 – 10:02

    EANS-News: Epigenomics Signs Distribution Deal with DATEKS for Epi proColon in Turkey

    Second distributor to be signed-up for Epi proColon - more expected to come shortly Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Company Information/Molecular diagnostics Subtitle: Second distributor to be signed-up for Epi proColon - more expected to come shortly BERLIN and ...